Check it out!
https://www.youtube.com/watch?v=-zvuZd28-0o&feature=youtu.be
Currently we are running the following studies on the drug-coated balloon technology:
-A randomized controlled trial of new-generation DCB vs new generation DES for the treatment of small coronary vessel disease: a spontaneous, multicenter clinical trial. You can find the study protocol in this page.
-the Falcon Registry: a prospective registry on the In.Pact Falcon (Medtronic) DCB, for any coronary clinical indication. This is a multicenter international registry. I am the Italian P.I. for this study. You can find the study protocol in this page.
-The Italian Elutax SV all-comers Registry: a retrospective multicenter registry on the use of the Elutax SV DCB for coronary applications. We are the coordinating center for this national study.
-The DCB Restore Registry: a retrospective multicenter registry on the use of the Restore DCB for coronary applications. We are the coordinating center for this study. I have the dream of running it internationally, and I’m working on this item.
https://www.radcliffecardiology.com/JIM-2020-Sirolimus-DCB-Bernardo-Cortese
About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.
After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.
Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.
Today we are presenting the last one:
“Mortality Increase and Paclitaxil-Coated Device Use” December 2019
About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.
After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.
Therefore, we are presenting our point of view regarding the topic, as expressed in some published editorials.
Today we are presenting the following one:
“The hypothesis of an increased mortality following paclitaxel coated device use in peripheral vascular interventions (and the emerging era of meta-analysis based evidence)” 22.10.19
About one year ago, a metanalysis conducted by Dr. Katsanos and Coll. showed an increase in mortality following the use of paclitaxel-coated balloons / stents when used for femoro-popliteal PTA. The whole sector was evidently shocked as a result to this metanalysis, and many actions (some of them absolutely unjustified) have been taken since then.
After one year, after a necessary cooling off period and further analyses, it is time for me to take a clear position on the matter.
Therefore, during the next weeks we are presenting our point of view regarding the topic, as expressed in some published editorials.
Today we are presenting the first one:
“Use of Paclitaxel-Eluting Technologies in the Femoropopliteal Segment Under Scrutiny Over Possible Link to Late All-Cause Mortality: Time to Panic or an Opportunity to Resurge?” 26.02.19